List of Excipients in Branded Drug LYMEPAK

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Chartwell RX LLC	LYMEPAK	doxycycline hyclate	62135-596	ANHYDROUS LACTOSE
Chartwell RX LLC	LYMEPAK	doxycycline hyclate	62135-596	CELLULOSE, MICROCRYSTALLINE
Chartwell RX LLC	LYMEPAK	doxycycline hyclate	62135-596	D&C YELLOW NO. 10
Chartwell RX LLC	LYMEPAK	doxycycline hyclate	62135-596	FD&C BLUE NO. 1

LYMEPAK Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

LYMEPAK is a doxycycline hyclate oral tablet positioned for Lyme disease treatment. Its commercial opportunity is driven less by active-ingredient exclusivity and more by formulation execution: gastrointestinal tolerability, swallowing, stability, dosing convenience, pediatric usability, and channel-specific packaging. Because doxycycline is a mature small-molecule antibiotic, LYMEPAK has no biosimilar exposure and faces substantial generic competition. A differentiated excipient strategy would need to support a regulatory pathway such as an ANDA with formulation matching or, for a clinically differentiated product, a 505(b)(2) application.

What is LYMEPAK and what excipients are commercially relevant?

LYMEPAK contains doxycycline hyclate, a tetracycline-class antibacterial. The product is labeled for the treatment of Lyme disease caused by Borrelia burgdorferi and is supplied as an oral tablet formulation.[1]

The commercial formulation priorities are:

Formulation priority	Excipient or technology response	Commercial objective
Tablet swallowability	Film coating, tablet-size reduction, optimized compression	Improve adherence and reduce substitution risk
Gastrointestinal tolerability	Controlled disintegration, lower local drug concentration, food-use instructions	Reduce discontinuation and complaints
Moisture and light protection	High-barrier blister, desiccant packaging, protective coating	Improve shelf life and distribution reliability
Taste and mouthfeel	Robust film coat, minimal tablet breakup in the mouth	Support patient acceptability
Pediatric or dysphagia use	Dispersible tablet, oral suspension, multiparticulate granules	Expand age and administration segments
Manufacturing robustness	Microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, or equivalent functional excipients	Reduce batch variability
Dose flexibility	Scored tablet or multiple strengths	Support weight-based and step-down prescribing

Doxycycline hyclate is hygroscopic relative to many conventional tablet ingredients and requires control of moisture exposure during granulation, compression, coating, and packaging. Excipients should be selected for compatibility with the salt form, low water activity, and predictable dissolution.

The final inactive-ingredient composition must be taken from the applicable LYMEPAK labeling and regulatory record. A generic development program cannot assume that a commercially available excipient profile is interchangeable without comparative dissolution, stability, and bioequivalence support.

What excipient strategy best fits a LYMEPAK generic?

The lowest-risk strategy is a conventional immediate-release film-coated tablet that matches the reference product’s critical quality attributes. The formulation should prioritize bioequivalence and manufacturability over novelty.

Immediate-release tablet strategy

A practical formulation platform would typically use:

• A diluent such as microcrystalline cellulose or lactose, subject to compatibility and reference-product matching.
• A superdisintegrant such as croscarmellose sodium or sodium starch glycolate.
• A lubricant such as magnesium stearate at a controlled concentration.
• Colloidal silicon dioxide to improve powder flow.
• A moisture-resistant film coat based on hypromellose or another established coating polymer.
• Opacifiers, plasticizers, and pigments only where needed for product identification and stability.

The critical formulation risks are over-lubrication, slow disintegration, dissolution drift, and moisture-mediated degradation. Magnesium stearate level and blending time require close control because excessive lubrication can reduce tablet tensile strength and retard dissolution.

A conventional immediate-release product offers the most direct ANDA path. It also has the weakest differentiation because many manufacturers can reproduce the dosage form.

Film-coating strategy

A thin, robust film coat can create commercial value without materially changing release. The coat should:

1. Reduce dusting and improve handling.
2. Mask bitterness if the tablet is chewed or held in the mouth.
3. Limit moisture uptake.
4. Provide color and imprint contrast.
5. Avoid meaningful changes to dissolution.

A high-barrier coating can support stability, but a coating that materially delays release may create a bioequivalence or product-performance issue. The coating process must be validated for uniformity, adhesion, curing, and residual moisture.

Dispersible or orally disintegrating strategy

A dispersible doxycycline tablet could address patients with dysphagia, adolescents, and selected pediatric populations. The principal challenges are taste, dose uniformity after dispersion, sedimentation, and the risk of dental exposure from tetracycline-class drugs.

A dispersible format may justify a 505(b)(2) strategy if it offers a clinically relevant administration benefit not available from existing tablets. The development program would need to support the proposed labeling, administration instructions, stability, and any differences in exposure or tolerability.

Oral suspension or granule strategy

A ready-to-use suspension offers greater administration flexibility but creates higher development and commercial risk. Key requirements include:

• Chemical stability after reconstitution.
• Uniformity throughout the dosing interval.
• Preservation and microbial control.
• Appropriate container closure.
• Shake-reconstitution performance.
• Acceptable taste and sedimentation behavior.

A dry powder for reconstitution can reduce stability risk compared with a ready-to-use liquid. The excipient system would likely require a suspending polymer, wetting agent, buffer or pH modifier, sweetener, flavor, and preservative system. Each added excipient increases regulatory and manufacturing complexity.

What formulation patents could protect a LYMEPAK follow-on product?

The strongest protectable features would be technical and product-specific rather than broad claims to doxycycline itself. Potential claim categories include:

Patent category	Example protected subject matter	Relative strength
Composition of matter	New doxycycline salt, co-crystal, or complex	High, but difficult and unlikely for a mature product
Formulation composition	Defined excipient ratios, polymer system, or stabilizer combination	Moderate if linked to measurable performance
Dosage form	Dispersible, chewable, orally disintegrating, or multiparticulate tablet	Moderate to high if technically distinctive
Release profile	Delayed-release or modified-release doxycycline system	Moderate, subject to clinical and bioequivalence requirements
Manufacturing process	Low-moisture granulation, coating, or packaging process	Moderate; enforcement can be difficult
Packaging	Moisture-control blister, desiccant system, or unit-dose configuration	Low to moderate
Method of use	Dosing regimen, duration, or patient subgroup	Variable and potentially limited by existing treatment practice

A formulation patent is strongest when the claims connect a defined composition to unexpected dissolution, stability, tolerability, or pharmacokinetic results. Broad claims covering routine excipient substitutions are vulnerable to obviousness challenges.

For an ANDA sponsor, patent risk should be assessed against Orange Book-listed patents for the reference product and against unlisted formulation, process, and packaging patents that may support separate commercial litigation. For a 505(b)(2) sponsor, the relevant patent certifications and potential Paragraph IV exposure depend on the listed patents and the proposed labeling.

What is the FDA regulatory status and Orange Book position of LYMEPAK?

LYMEPAK is regulated as a small-molecule oral doxycycline product, not as a biologic. The applicable pathways are:

• ANDA for a therapeutically equivalent generic tablet.
• 505(b)(2) NDA for a new dosage form, route, formulation, or clinically differentiated administration profile.
• Supplemental NDA for changes to an existing approved product, where applicable.

FDA Orange Book analysis should establish:

1. The exact reference listed drug and strength.
2. Whether LYMEPAK is itself the reference listed drug or a generic product.
3. Therapeutic-equivalence codes.
4. Listed patents and their expiration dates.
5. Any pediatric exclusivity or other statutory exclusivity.
6. Whether the product is eligible for substitution under state pharmacy rules.

Doxycycline products are generally mature products with multiple approved manufacturers. The main regulatory barrier is therefore not active-ingredient novelty. It is demonstrating equivalent performance, managing labeling differences, and securing reliable commercial supply.

A Paragraph IV challenge is commercially relevant only if an Orange Book-listed patent remains active and claims the reference product, formulation, or approved use. A formulation developer should not assume that a branded product name creates meaningful patent protection.

When does LYMEPAK lose exclusivity?

LYMEPAK’s commercial exclusivity is likely controlled by the underlying doxycycline market, not by a long-lived proprietary active-ingredient patent. The relevant timing depends on the product’s approval basis and any listed patents or regulatory exclusivities.

Exclusivity issue	Relevance to LYMEPAK
New chemical entity exclusivity	Generally not expected for doxycycline hyclate
Orphan-drug exclusivity	Not expected for conventional Lyme disease treatment
Pediatric exclusivity	Possible only if specifically granted for an eligible product
Orange Book patent term	Must be confirmed from current FDA listings
Formulation patent term	Relevant if a proprietary dosage form is claimed
ANDA approval timing	Depends on patent certifications, litigation, and settlement terms
180-day generic exclusivity	Relevant to a first Paragraph IV ANDA applicant, if statutory conditions are met

A precise expiration date cannot be inferred from the brand name alone. FDA Orange Book records and the applicable patent files control the analysis.[2]

How strong is the patent estate for LYMEPAK?

The patent estate is likely weak to moderate from a generic-barrier perspective unless LYMEPAK relies on a specifically patented dosage form or manufacturing process. Doxycycline has a long history of use, and conventional immediate-release tablets are difficult to protect broadly.

Factors supporting generic entry

• Mature active pharmaceutical ingredient.
• Established oral tablet technology.
• Multiple doxycycline products.
• Limited opportunity to claim basic excipient combinations.
• No biosimilar pathway or biologic manufacturing barrier.
• Familiar FDA bioequivalence framework.

Factors that could delay entry

• A valid listed formulation patent.
• A Paragraph IV lawsuit filed within the statutory window.
• Limited API suppliers with acceptable regulatory histories.
• Stability failures caused by moisture sensitivity.
• Device, packaging, or dosage-form patents.
• Settlement agreements restricting launch timing.

The strongest defensible platform would combine a differentiated dosage form with manufacturing know-how, validated stability, and a commercial package that is difficult to replicate economically.

What commercial opportunities exist for LYMEPAK excipient innovation?

1. Pediatric and dysphagia products

A dispersible or taste-masked tablet could target patients who cannot reliably swallow conventional tablets. The opportunity is strongest where the product supports accurate dosing and avoids the handling burden of a liquid suspension.

2. Unit-dose adherence packaging

Lyme disease treatment often involves a defined course. Calendar blister packs, unit-dose packaging, and pharmacist-ready adherence packs can reduce missed doses and differentiate a commodity tablet without changing the active formulation.

3. Gastrointestinal tolerability

A formulation that reduces esophageal irritation or improves administration with water and food could generate physician and patient value. The labeling must remain consistent with doxycycline safety information, including administration instructions intended to reduce esophageal injury.

4. Institutional and public-health supply

Unit-dose, tamper-evident, and moisture-protective packaging may support public-health procurement, urgent-care clinics, military medicine, and telehealth fulfillment. Procurement buyers generally value shelf life, supply reliability, packaging efficiency, and low total acquisition cost.

5. Private-label and licensing programs

The most practical licensing targets are manufacturers with:

• Approved doxycycline API sources.
• ANDA or 505(b)(2) development capability.
• Established antibiotic manufacturing capacity.
• Pediatric or specialty-pharmacy distribution.
• A commercial portfolio in infectious disease.

A formulation owner could license the product to an established generic company while retaining rights to a specific dosage form, geographic territory, or channel.

How does LYMEPAK compare with other doxycycline products?

Attribute	Conventional doxycycline generic	LYMEPAK-type branded tablet	Differentiated follow-on
Active ingredient	Doxycycline hyclate or monohydrate	Doxycycline hyclate	Doxycycline salt or novel formulation
Primary value	Low cost and supply	Brand identification and channel access	Administration, tolerability, or adherence
Patent barrier	Usually low	Product-specific	Potentially moderate
FDA pathway	ANDA	NDA or generic approval basis	ANDA or 505(b)(2)
Biosimilar risk	None	None	None
Pricing power	Low	Limited to moderate	Moderate if clinically differentiated
Main risk	Price erosion	Generic substitution	Development and reimbursement

The main competitive threat is conventional generic doxycycline, not a biosimilar. A premium product must therefore produce measurable value through dosage form, patient population, packaging, or distribution.

What generic launch scenarios exist for LYMEPAK?

Immediate generic launch

A conventional tablet sponsor could file an ANDA and enter after satisfying patent and regulatory requirements. Pricing would likely decline rapidly if several approved suppliers enter.

Authorized generic or licensed launch

The brand owner or a licensee could launch a product under a separate label or commercial agreement. This approach can preserve some channel control but usually limits price differentiation.

505(b)(2) differentiated launch

A dispersible, pediatric, modified-release, or adherence-focused product could pursue a 505(b)(2) strategy. The opportunity is larger, but so are clinical, regulatory, and reimbursement requirements.

Geographic expansion

Outside the United States, the product may compete through national marketing authorizations, local generic registrations, or licensing. Patent coverage, trademark rights, pediatric requirements, and excipient acceptance vary by jurisdiction. EU, Canadian, Australian, and emerging-market strategies should be analyzed separately from U.S. Orange Book status.

Key Takeaways

• LYMEPAK is a doxycycline hyclate oral tablet for Lyme disease treatment.
• The active ingredient is mature, so formulation and commercial execution are the main sources of defensibility.
• The lowest-risk development path is a conventional immediate-release film-coated tablet with reference-matched dissolution and stability.
• The strongest commercial opportunities are dispersible or pediatric dosage forms, taste masking, moisture-protective packaging, and adherence-oriented unit dosing.
• LYMEPAK has no biosimilar risk because doxycycline is a small molecule.
• Generic entry risk is high unless a valid listed patent, proprietary dosage form, or enforceable manufacturing barrier applies.
• Exact patent expiration dates and Orange Book status must be determined from current FDA records for the relevant product and reference listed drug.
• A 505(b)(2) strategy may support premium positioning, but it requires a clinically meaningful formulation or administration advantage.

FAQs About LYMEPAK Excipient and Commercial Strategy

Can lactose be used in a generic LYMEPAK formulation?

Lactose may be technically suitable, but compatibility, moisture sensitivity, dose uniformity, dissolution, and reference-product composition must be assessed. It may also be unsuitable for specific patient populations or commercial positioning.

Would a chewable LYMEPAK tablet have a stronger patent position?

Potentially. A chewable product can support composition, taste-masking, and dosage-form claims. Patent strength depends on whether the formulation delivers unexpected taste, stability, dissolution, or pharmacokinetic results.

Is doxycycline hyclate or doxycycline monohydrate better for a LYMEPAK follow-on?

Neither salt is universally superior. The choice affects solubility, hygroscopicity, tablet performance, tolerability, API sourcing, and bioequivalence strategy. The reference product and proposed labeling determine the regulatory implications.

Can a moisture-resistant blister package create market exclusivity?

Packaging alone rarely creates strong market exclusivity. It can support a patent or trade-secret position if the system solves a measurable stability problem, but its larger value is often shelf-life protection and supply-chain reliability.

Is a pediatric doxycycline product commercially attractive?

It can be attractive where swallowing difficulty, dose flexibility, and adherence are significant barriers. Commercial success depends on taste, dosing accuracy, age-specific labeling, reimbursement, and the ability to avoid excessive dental-exposure concerns associated with tetracycline-class therapy.

References

1. U.S. National Library of Medicine. (n.d.). LYMEPAK- doxycycline hyclate tablet, film coated. DailyMed.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.
3. U.S. Food and Drug Administration. (2024). ANDA submissions: Product-specific guidances for industry. FDA.
4. U.S. Food and Drug Administration. (2023). Guidance for industry: Applications covered by section 505(b)(2). FDA.
5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.